Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Scott R. Granter(Brigham and Women's Hospital), Corey Cutler(Harvard University), John Koreth(Otsuka (Japan)), Masahiro Hirakawa(Sapporo Medical University), Yi‐Bin Chen(Massachusetts General Hospital), Vincent T. Ho(Dana-Farber Cancer Institute), Asad Bashey, Haesook T. Kim(Dana-Farber Cancer Institute), Catherine J. Wu(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Philippe Armand(Harvard University), Joseph H. Antin(Dana-Farber Cancer Institute), Chensheng W. Zhou(Dana-Farber Cancer Institute), Pavan Bachireddy(Broad Institute), Scott J. Rodig(Brigham and Women's Hospital), Mariano Severgnini(Dana-Farber Cancer Institute), Alexander Lukez(Dana-Farber Cancer Institute), Michaela Bowden(Brigham and Women's Hospital), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Nicole R. LeBoeuf(Dana-Farber Brigham Cancer Center), Jason L. Hornick(Harvard University), F. Stephen Hodi(Harvard University), Caitlin Costello(University of California San Diego), Howard Streicher(National Cancer Institute), Rebecca Liguori(Dana-Farber Cancer Institute), Peter A. McSweeney(Colorado Blood Cancer Institute), Edward D. Ball(Sheba Medical Center), Michael S. Rooney(BioNTech (United States)), Alexandra Savell(Dana-Farber Cancer Institute), Jerome Ritz(Dana-Farber Cancer Institute)
Cited by 595
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k